SG10202110077QA - Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab - Google Patents
Uses for and article of manufacture including her2 dimerization inhibitor pertuzumabInfo
- Publication number
- SG10202110077QA SG10202110077QA SG10202110077QA SG10202110077QA SG 10202110077Q A SG10202110077Q A SG 10202110077QA SG 10202110077Q A SG10202110077Q A SG 10202110077QA SG 10202110077Q A SG10202110077Q A SG 10202110077QA
- Authority
- SG
- Singapore
- Prior art keywords
- article
- manufacture including
- dimerization inhibitor
- her2 dimerization
- including her2
- Prior art date
Links
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 238000006471 dimerization reaction Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 229960002087 pertuzumab Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Packages (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547535P | 2011-10-14 | 2011-10-14 | |
| US201161567015P | 2011-12-05 | 2011-12-05 | |
| US201261657669P | 2012-06-08 | 2012-06-08 | |
| US201261682037P | 2012-08-10 | 2012-08-10 | |
| US201261694584P | 2012-08-29 | 2012-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202110077QA true SG10202110077QA (en) | 2021-10-28 |
Family
ID=47073543
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201401432XA SG11201401432XA (en) | 2011-10-14 | 2012-10-11 | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| SG10201606756PA SG10201606756PA (en) | 2011-10-14 | 2012-10-11 | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| SG10202110077Q SG10202110077QA (en) | 2011-10-14 | 2012-10-11 | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201401432XA SG11201401432XA (en) | 2011-10-14 | 2012-10-11 | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| SG10201606756PA SG10201606756PA (en) | 2011-10-14 | 2012-10-11 | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
Country Status (29)
| Country | Link |
|---|---|
| US (9) | US20130095172A1 (en) |
| EP (5) | EP4234033A3 (en) |
| JP (8) | JP2014530235A (en) |
| KR (4) | KR20230028585A (en) |
| CN (8) | CN104334189A (en) |
| AU (4) | AU2012322797B2 (en) |
| BR (1) | BR112014007521A8 (en) |
| CL (1) | CL2014000889A1 (en) |
| DK (1) | DK2766040T3 (en) |
| EA (1) | EA034390B1 (en) |
| ES (1) | ES2736005T3 (en) |
| HK (1) | HK1202242A1 (en) |
| HR (1) | HRP20191247T1 (en) |
| HU (1) | HUE044352T2 (en) |
| IL (4) | IL301603A (en) |
| IN (1) | IN2014CN02703A (en) |
| LT (1) | LT2766040T (en) |
| MX (2) | MX2014004021A (en) |
| MY (2) | MY194408A (en) |
| PE (1) | PE20142363A1 (en) |
| PH (1) | PH12019500519A1 (en) |
| PL (1) | PL2766040T3 (en) |
| PT (1) | PT2766040T (en) |
| RS (1) | RS58944B1 (en) |
| SG (3) | SG11201401432XA (en) |
| SI (1) | SI2766040T1 (en) |
| UA (2) | UA123092C2 (en) |
| WO (1) | WO2013055874A2 (en) |
| ZA (1) | ZA201401259B (en) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
| JP2008531576A (en) | 2005-02-23 | 2008-08-14 | ジェネンテック・インコーポレーテッド | Prolonged time to disease progression or survival in cancer patients using HER dimerization inhibitors |
| NZ578824A (en) | 2007-03-02 | 2012-03-30 | Genentech Inc | Predicting response to a her dimerisation inhibitor based on low her3 expression |
| US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
| TWI472339B (en) | 2008-01-30 | 2015-02-11 | Genentech Inc | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
| BRPI0812682A2 (en) | 2008-06-16 | 2010-06-22 | Genentech Inc | metastatic breast cancer treatment |
| JP5677970B2 (en) | 2008-11-03 | 2015-02-25 | シンタルガ・ビーブイ | Novel CC-1065 analogs and complexes thereof |
| LT3056203T (en) | 2010-04-21 | 2018-03-26 | Syntarga B.V. | Conjugates of cc-1065 analogs and bifunctional linkers |
| PE20142363A1 (en) | 2011-10-14 | 2015-01-30 | Genentech Inc | USES AND MANUFACTURING ARTICLE INCLUDING HER2 PERTUZUMAB DIMERIZATION INHIBITOR |
| AR094403A1 (en) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | ANTI-HER3 ANTIBODY COMBINATION THERAPY |
| AU2014254086B2 (en) | 2013-04-16 | 2018-07-05 | Genentech, Inc. | Pertuzumab variants and evaluation thereof |
| MX2015017655A (en) * | 2013-06-19 | 2016-04-15 | Seragon Pharmaceuticals Inc | Estrogen receptor modulator and uses thereof. |
| ES2763429T5 (en) | 2013-12-17 | 2023-06-21 | Hoffmann La Roche | Methods of treating cancers using PD-1 axis binding antagonists and taxanes |
| CN104726462A (en) * | 2013-12-20 | 2015-06-24 | 北京天广实生物技术股份有限公司 | Anti-HER2 humanized antibody MIL41, and preparation method and applications thereof |
| LT3092010T (en) | 2014-01-10 | 2018-10-25 | Synthon Biopharmaceuticals B.V. | Method for purifying cys-linked antibody-drug conjugates |
| JP6224268B2 (en) * | 2014-01-10 | 2017-11-01 | シントン・バイオファーマシューティカルズ・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． | Duocarmycin ADC for use in the treatment of endometrial cancer |
| KR102344354B1 (en) * | 2014-01-10 | 2021-12-28 | 비온디스 비.브이. | Duocarmycin adcs showing improved in vivo antitumor activity |
| WO2016094341A1 (en) * | 2014-12-08 | 2016-06-16 | Synta Pharmaceuticals Corp. | Triple combination therapy, comprising ganetespib, a taxane and an antibody, for use in the treatment of her2 positive breast cancer |
| KR102067327B1 (en) | 2015-05-29 | 2020-02-11 | 익스프레션 패톨로지, 인크. | Quantifying Her2 Protein for Optimal Cancer Treatment |
| AU2016280070B2 (en) | 2015-06-17 | 2022-09-15 | Genentech, Inc. | Methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists and taxanes |
| MA45324A (en) * | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | POLYTHERAPY USING ADC-LIV1 AND CHEMOTHERAPEUTIC AGENT |
| AU2017355432A1 (en) * | 2016-11-04 | 2019-05-16 | F. Hoffmann-La Roche Ag | Treatment of HER2-positive breast cancer |
| CA3046092A1 (en) * | 2016-12-28 | 2018-07-05 | Genentech, Inc. | Treatment of advanced her2 expressing cancer |
| DK3570884T3 (en) * | 2017-01-17 | 2020-11-30 | Genentech Inc | Subcutaneous HER2 antibody formulations |
| CN116850283A (en) * | 2017-03-02 | 2023-10-10 | 豪夫迈·罗氏有限公司 | Adjuvant therapy of HER2 positive breast cancer |
| WO2020080892A1 (en) * | 2018-10-19 | 2020-04-23 | 주식회사 프로티나 | Drug targeting heterodimer of her2 and her3 and method for screening same |
| WO2020240417A1 (en) * | 2019-05-27 | 2020-12-03 | Tolmar International Limited | Leuprolide acetate compositions and methods of using the same to treat breast cancer |
| AU2020303572A1 (en) | 2019-06-28 | 2022-01-20 | Board Of Regents, The University Of Texas System | Preparation of preliposomal Annamycin lyophilizate |
| WO2020264161A1 (en) * | 2019-06-28 | 2020-12-30 | Donald Picker | Method of reconstituting liposomal annamycin |
| US20230175069A1 (en) * | 2020-04-29 | 2023-06-08 | University Of Pittsburgh-Of The Commonweal Th System Of Higher Education | Compositions and methods for detecting gene fusions of esr1 and ccdc170 for determining increased resistance to endocrine therapy and for cancer treatment |
| CN111710425A (en) * | 2020-06-19 | 2020-09-25 | 复旦大学附属中山医院 | Method, system and device for evaluating cardiotoxicity of immune checkpoint inhibitor |
| WO2023108012A1 (en) * | 2021-12-07 | 2023-06-15 | Io Therapeutics, Inc. | Use of an rxr agonist and taxanes in treating her2+ cancers |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4933294A (en) | 1984-01-30 | 1990-06-12 | Icrf Patents Limited | Method of detecting truncated epidermal growth factor receptors |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| DK0474727T3 (en) | 1989-05-19 | 1998-01-12 | Genentech Inc | HER2 extracellular domain |
| WO1991005264A1 (en) | 1989-09-29 | 1991-04-18 | Oncogenetics Partners | Detection and quantification of neu related proteins in the biological fluids of humans |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
| PT1516628E (en) | 1995-07-27 | 2013-09-24 | Genentech Inc | Stable isotonic lyophilized protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| EP0852951A1 (en) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals |
| EP1900751B1 (en) | 1996-11-27 | 2009-12-09 | Genentech, Inc. | Affinity purification of polypeptide on protein a matrix |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| ATE398464T1 (en) | 1998-03-27 | 2008-07-15 | Genentech Inc | SYNERGY BETWEEN APO-2 LIGAND AND ANTIBODIES AGAINST HER-2 |
| ES2261589T3 (en) | 1998-05-06 | 2006-11-16 | Genentech, Inc. | ANTI-HER2 ANTIBODY COMPOSITION. |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| JP5623681B2 (en) | 1999-05-14 | 2014-11-12 | ジェネンテック， インコーポレイテッド | Treatment with anti-ErbB2 antibody |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| KR100754049B1 (en) | 1999-06-25 | 2007-08-31 | 제넨테크, 인크. | ANTI-ErbB2 ANTIBODIES AND COMPOSITION USED IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING PROSTATE CANCER |
| US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| GEP20104998B (en) | 1999-06-25 | 2010-06-10 | Genentech Inc | Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer |
| US6627196B1 (en) | 1999-08-27 | 2003-09-30 | Genentech, Inc. | Dosages for treatment with anti-ErbB2 antibodies |
| US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| KR20130056201A (en) | 2000-05-19 | 2013-05-29 | 제넨테크, 인크. | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
| KR20100031769A (en) | 2000-12-28 | 2010-03-24 | 알투스 파마슈티컬스 인코포레이티드 | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| DK1501856T3 (en) | 2002-04-10 | 2013-03-25 | Genentech Inc | Anti-HER2 antibody variants |
| CN102295703A (en) | 2002-07-15 | 2011-12-28 | 健泰科生物技术公司 | Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies |
| ES2629602T5 (en) | 2002-09-11 | 2021-06-08 | Genentech Inc | Protein purification |
| US20060100168A1 (en) * | 2002-09-30 | 2006-05-11 | The Trustee Of Boston University | Method of treating cancer using adenosine and its analogs |
| CA2506320A1 (en) | 2002-11-21 | 2004-06-10 | Genentech, Inc. | Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies |
| EP3722309A1 (en) | 2003-07-28 | 2020-10-14 | Genentech, Inc. | Reducing protein a leaching during protein a affinity chromatography |
| CA2563341C (en) | 2004-04-08 | 2014-10-21 | David B. Agus | Erbb antagonists for pain therapy |
| JP5234734B2 (en) | 2004-06-01 | 2013-07-10 | ジェネンテック， インコーポレイテッド | Antibody-drug conjugates and methods |
| SV2006002143A (en) | 2004-06-16 | 2006-01-26 | Genentech Inc | USE OF AN ANTIBODY FOR THE TREATMENT OF CANCER RESISTANT TO PLATINUM |
| US20050280299A1 (en) | 2004-06-18 | 2005-12-22 | Alfmeier Corporation | Mounting adaptor for seat assembly, and seat assembly having mounting adaptor |
| UA90480C2 (en) | 2004-07-22 | 2010-05-11 | Джэнэнтэк, Инк. | HER2 antibody composition exhibiting anticancer activity |
| JP2008510466A (en) | 2004-08-19 | 2008-04-10 | ジェネンテック・インコーポレーテッド | Polypeptide variants with altered effector function |
| JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
| EP1819735A1 (en) * | 2004-11-04 | 2007-08-22 | Pfizer Products Inc. | Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer |
| CA2587519A1 (en) | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
| AU2005325200A1 (en) | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of HER antibodies |
| PL3248600T3 (en) * | 2005-02-18 | 2020-09-07 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| JP2008531576A (en) | 2005-02-23 | 2008-08-14 | ジェネンテック・インコーポレーテッド | Prolonged time to disease progression or survival in cancer patients using HER dimerization inhibitors |
| TW200642695A (en) | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
| US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
| JP2006316040A (en) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(r) adjuvant treatment |
| US20070009976A1 (en) | 2005-07-06 | 2007-01-11 | Helmut Lenz | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody |
| PE20070207A1 (en) | 2005-07-22 | 2007-03-09 | Genentech Inc | COMBINED TREATMENT OF TUMORS THAT EXPRESS HER |
| US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| CA2654584A1 (en) * | 2006-06-05 | 2007-12-21 | Genentech, Inc. | Extending survival of cancer patients with elevated levels of egf or tgf-alpha |
| JP5305904B2 (en) | 2006-06-14 | 2013-10-02 | 株式会社キャタラー | Exhaust gas purification catalyst |
| BRPI0715829A2 (en) | 2006-08-21 | 2013-07-23 | Hoffmann La Roche | tumor therapy with an anti-vegf antibody |
| WO2008031531A1 (en) * | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
| NZ578824A (en) * | 2007-03-02 | 2012-03-30 | Genentech Inc | Predicting response to a her dimerisation inhibitor based on low her3 expression |
| JP5373776B2 (en) | 2007-06-06 | 2013-12-18 | エフ．ホフマン−ラ ロシュ アーゲー | A composition comprising an unlabeled primary monoclonal antibody that binds to a tumor antigen and a non-cross-reactive secondary monoclonal antibody labeled with a NIR fluorescein label |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| US20100298156A1 (en) | 2007-06-08 | 2010-11-25 | Si Tuen Lee-Hoeflich | Gene expression markers of tumor resistance to her2 inhibitor treatment |
| CL2008002687A1 (en) | 2007-09-12 | 2009-01-16 | Genentech Inc | Use of a pharmaceutical combination of a compound derived from thieno [3,2-d] pyrimidine with a chemotherapeutic agent in the treatment of a hyperproliferative disorder; pharmaceutical kit. |
| EP2211854A4 (en) * | 2007-10-19 | 2011-01-12 | Bipar Sciences Inc | Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors |
| ES2666170T3 (en) | 2007-10-30 | 2018-05-03 | Genentech, Inc. | Purification of antibodies by cation exchange chromatography |
| TWI472339B (en) | 2008-01-30 | 2015-02-11 | Genentech Inc | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
| US20090203015A1 (en) * | 2008-02-13 | 2009-08-13 | Celera Corporation | Multiplex assays for hormonal and growth factor receptors, and uses thereof |
| US20090226455A1 (en) | 2008-03-06 | 2009-09-10 | Genentech, Inc. | Combination therapy with c-met and her antagonists |
| SI2254571T1 (en) | 2008-03-18 | 2015-10-30 | Genentech, Inc. | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| BRPI0812682A2 (en) * | 2008-06-16 | 2010-06-22 | Genentech Inc | metastatic breast cancer treatment |
| EP2752189B1 (en) * | 2008-11-22 | 2016-10-26 | F. Hoffmann-La Roche AG | Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer |
| US20120121586A1 (en) | 2009-05-29 | 2012-05-17 | Astrid Kiermaier | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| WO2011069074A2 (en) * | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1 |
| PE20142363A1 (en) | 2011-10-14 | 2015-01-30 | Genentech Inc | USES AND MANUFACTURING ARTICLE INCLUDING HER2 PERTUZUMAB DIMERIZATION INHIBITOR |
-
2012
- 2012-10-11 PE PE2014000507A patent/PE20142363A1/en active IP Right Grant
- 2012-10-11 CN CN201280061896.3A patent/CN104334189A/en active Pending
- 2012-10-11 MY MYPI2019003795A patent/MY194408A/en unknown
- 2012-10-11 KR KR1020237005562A patent/KR20230028585A/en not_active Application Discontinuation
- 2012-10-11 CN CN202310701159.5A patent/CN116808199A/en active Pending
- 2012-10-11 SG SG11201401432XA patent/SG11201401432XA/en unknown
- 2012-10-11 KR KR1020147009738A patent/KR102099991B1/en active IP Right Grant
- 2012-10-11 EP EP23172794.2A patent/EP4234033A3/en active Pending
- 2012-10-11 LT LTEP12778010.4T patent/LT2766040T/en unknown
- 2012-10-11 AU AU2012322797A patent/AU2012322797B2/en active Active
- 2012-10-11 EP EP23172847.8A patent/EP4241849A3/en active Pending
- 2012-10-11 WO PCT/US2012/059683 patent/WO2013055874A2/en active Application Filing
- 2012-10-11 PL PL12778010T patent/PL2766040T3/en unknown
- 2012-10-11 HU HUE12778010 patent/HUE044352T2/en unknown
- 2012-10-11 ES ES12778010T patent/ES2736005T3/en active Active
- 2012-10-11 MX MX2014004021A patent/MX2014004021A/en active IP Right Grant
- 2012-10-11 SG SG10201606756PA patent/SG10201606756PA/en unknown
- 2012-10-11 IL IL301603A patent/IL301603A/en unknown
- 2012-10-11 CN CN202210486683.0A patent/CN114984205A/en active Pending
- 2012-10-11 CN CN202310108240.2A patent/CN116271013A/en active Pending
- 2012-10-11 EP EP23172860.1A patent/EP4234034A3/en active Pending
- 2012-10-11 DK DK12778010.4T patent/DK2766040T3/en active
- 2012-10-11 SG SG10202110077Q patent/SG10202110077QA/en unknown
- 2012-10-11 IN IN2703CHN2014 patent/IN2014CN02703A/en unknown
- 2012-10-11 CN CN202310135044.4A patent/CN116236569A/en active Pending
- 2012-10-11 RS RS20190845A patent/RS58944B1/en unknown
- 2012-10-11 IL IL309917A patent/IL309917A/en unknown
- 2012-10-11 SI SI201231637T patent/SI2766040T1/en unknown
- 2012-10-11 BR BR112014007521A patent/BR112014007521A8/en not_active Application Discontinuation
- 2012-10-11 KR KR1020177004681A patent/KR102502545B1/en active IP Right Grant
- 2012-10-11 UA UAA201709999A patent/UA123092C2/en unknown
- 2012-10-11 EP EP19165341.9A patent/EP3598981A3/en not_active Withdrawn
- 2012-10-11 US US13/649,591 patent/US20130095172A1/en not_active Abandoned
- 2012-10-11 MY MYPI2014001060A patent/MY172326A/en unknown
- 2012-10-11 CN CN201811518146.XA patent/CN109908341B/en active Active
- 2012-10-11 CN CN202310820523.XA patent/CN117018187A/en active Pending
- 2012-10-11 PT PT12778010T patent/PT2766040T/en unknown
- 2012-10-11 EA EA201490779A patent/EA034390B1/en active Protection Beyond IP Right Term
- 2012-10-11 EP EP12778010.4A patent/EP2766040B1/en not_active Revoked
- 2012-10-11 JP JP2014535859A patent/JP2014530235A/en not_active Withdrawn
- 2012-10-11 CN CN202310064889.9A patent/CN116271011B/en active Active
- 2012-10-11 KR KR1020237015216A patent/KR20230073340A/en active Application Filing
- 2012-11-10 UA UAA201405091A patent/UA116095C2/en unknown
-
2014
- 2014-02-19 ZA ZA2014/01259A patent/ZA201401259B/en unknown
- 2014-03-06 IL IL231350A patent/IL231350B2/en unknown
- 2014-04-03 MX MX2019009153A patent/MX2019009153A/en unknown
- 2014-04-09 CL CL2014000889A patent/CL2014000889A1/en unknown
-
2015
- 2015-03-17 HK HK15102729.7A patent/HK1202242A1/en unknown
-
2016
- 2016-03-02 US US15/058,520 patent/US20160175438A1/en not_active Abandoned
- 2016-07-15 AU AU2016204962A patent/AU2016204962B2/en active Active
-
2017
- 2017-06-28 JP JP2017125883A patent/JP2017222663A/en not_active Withdrawn
-
2018
- 2018-06-05 AU AU2018203970A patent/AU2018203970B2/en active Active
- 2018-09-06 US US16/123,809 patent/US20190117769A1/en not_active Abandoned
-
2019
- 2019-03-11 PH PH12019500519A patent/PH12019500519A1/en unknown
- 2019-07-11 HR HRP20191247TT patent/HRP20191247T1/en unknown
- 2019-10-02 JP JP2019182187A patent/JP6646785B1/en active Active
- 2019-11-04 AU AU2019261666A patent/AU2019261666B2/en active Active
-
2020
- 2020-01-10 JP JP2020002531A patent/JP2020090507A/en not_active Withdrawn
- 2020-02-20 US US16/796,163 patent/US20200206348A1/en not_active Abandoned
- 2020-08-13 US US16/992,966 patent/US20210015919A1/en not_active Abandoned
- 2020-08-17 US US16/994,950 patent/US20200376120A1/en not_active Abandoned
-
2021
- 2021-10-03 IL IL286921A patent/IL286921A/en unknown
-
2022
- 2022-01-06 JP JP2022000876A patent/JP2022062010A/en not_active Withdrawn
- 2022-03-28 US US17/656,732 patent/US20220362379A1/en active Pending
-
2023
- 2023-04-28 US US18/309,452 patent/US20230277663A1/en active Pending
- 2023-04-28 US US18/309,488 patent/US20230277664A1/en active Pending
- 2023-05-01 JP JP2023075388A patent/JP7303957B1/en active Active
- 2023-05-01 JP JP2023075391A patent/JP7352760B2/en active Active
- 2023-09-15 JP JP2023150231A patent/JP2024009803A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1202242A1 (en) | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab her2 her2 | |
| SG11201400630WA (en) | Abrasive article and method of forming | |
| AU347566S (en) | Article of jewellery | |
| EP2726247A4 (en) | Abrasive article and method of making | |
| EP2866975A4 (en) | Abrasive article and method of forming | |
| EP2678018A4 (en) | Combination of kanase inhibitors and uses thereof | |
| ZA201305403B (en) | Abrasive article and method of forming | |
| EP2647498A4 (en) | Antifouling article and method for producing same | |
| EP2866972A4 (en) | Abrasive article and method of forming | |
| IL232186A0 (en) | Method of forming hemostatic products | |
| EP2772483A4 (en) | 4-aminocarbazole compound and use of same | |
| EP2665725A4 (en) | Bicyclic inhibitors of alk | |
| ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
| GB201107692D0 (en) | Sterilisation of packed articles | |
| IL213865A0 (en) | Antiballistic article and method of producing same | |
| IL233381A0 (en) | Abrasive articles and method of forming same | |
| EP2747975A4 (en) | An article of manufacture and method for its preparation | |
| EP2724696A4 (en) | Worn article and method for producing same | |
| HK1210598A1 (en) | Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation -- | |
| EP2709999A4 (en) | Quinazoline-7-ether compounds and methods of use | |
| GB2493937B (en) | Articles of Kitchenware | |
| GB2492864B (en) | Article of footwear | |
| EP2798034A4 (en) | Bonded abrasive article and method of forming | |
| EP2665727A4 (en) | Bicyclic carboxamide inhibitors of kinases | |
| EP2900423A4 (en) | Abrasive article and method of forming |